We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
More than two years after receiving an FDA rejection, Mesoblast has resubmitted its biologics license application (BLA) for remestemcel-L, a treatment for children afflicted with steroid-refractory acute graft vs. host disease (SR-aGVHD). Read More
Amgen finally launched Amjevita (adalimumab-atto) in the U.S. yesterday, releasing the first rival to AbbVie’s mega-blockbuster anti-inflammatory drug, Humira. Read More
Cassava Sciences is claiming a phase 2 win with its investigational Alzheimer’s treatment simufilam in patients with mild-moderate disease — but the open-label study lacks a placebo comparator, and the topline numbers didn’t come with context indicating their statistical validity. Read More
The FDA’s Antimicrobial Drugs Advisory Committee gave a 14-1 thumbs-up yesterday for Cidara Therapeutics’ rezafungin, an investigational injection intended to treat candidemia and invasive candidiasis in adults who have no other treatment options. Read More